Mesothelioma Patients Can Benefit from Personalized Cancer Therapies

Mesothelioma researchers have long favored targeted cancer therapies, and this week that approach was supported by the results of a study out of the University of California San Diego. Following the establishment of a multidisciplinary molecular tumor board at the renowned facility, doctors found that those patients who were treated using precision medicine strategies experienced longer periods without disease progression or of overall survival.

Allowing Molecular Tumor Makeup to Guide Treatment Can Benefit Mesothelioma Patients

It is not immediately clear whether there were any mesothelioma patients among the 429 patients evaluated by the Moore’s Cancer Center at UC San Diego Health molecular tumor board. According to lead scientist and senior author of the study Razelle Kurzrock, MD, director of the Center for Personalized Cancer, the study ‘s conclusions were specifically written to address all types of cancer. 

The board was created so that physicians treating cancer patients could be advised on precision medicine care options based upon their individual molecular tumor makeup. Their follow-up revealed that 62 percent of patients were provided at least one of the drugs that the board recommended, and twenty percent were provided the exact course of treatment suggested. 

Mesothelioma Patients Hope for Similar Positive Results from Personalized Medicine Approach 

Mesothelioma physicians have long been working towards providing a tailored approach for their patients. These most recent results, published in the October 2, 2020 online issue of Nature Communications, encourages their previous work. 

“Patients who underwent a molecular tumor board-recommended therapy were better matched to genomic alterations in their cancer and had improved outcomes,” said Kurzrock. “The three-year survival for patients with the highest degree of matching and who received a personalized cancer therapy was approximately 55 percent compared to 25 percent in patients who received therapy that was unmatched or had low degrees of matching.” Physicians chose not to follow the tumor board’s recommendation in 38 percent of cases, opting for a traditional approach instead. Their patients suffered for it, experiencing lower overall survival rates and shorter periods of progression-free survival.

By working with physicians with expertise in personalized medicine, mesothelioma patients can experience better outcomes. For information on where to find these practitioners, contact the Patient Advocates at today at 1-800-692-8608.

Terri Heimann Oppenheimer

Terri Oppenheimer

Terri Heimann Oppenheimer is the head writer of our news blog. She graduated from the College of William and Mary with a degree in English. Terri believes that knowledge is power and she is committed to sharing news about the impact of mesothelioma, the latest research and medical breakthroughs, and victims’ stories.

Learn More About And Contact Terri
Get Help Contacting
This field is for validation purposes and should be left unchanged.
24/7 Live Chat
Online Now